Skip to content

Understanding the Truth: Why No Shingles Vaccine After 79?

4 min read

The Centers for Disease Control and Prevention (CDC) recommends the Shingrix shingles vaccine for all healthy adults aged 50 and older, with no maximum age limit. So, where does the question, "Why no shingles vaccine after 79?" come from, and is there any truth to it?

Quick Summary

Despite a common misconception, the CDC and other health experts confirm there is no maximum age for the modern Shingrix shingles vaccine. The confusion likely stems from outdated policies concerning the older, less effective Zostavax vaccine, which had a less durable effect in older individuals.

Key Points

  • No Maximum Age: The modern Shingrix vaccine does not have an upper age limit, contrary to an outdated misconception.

  • Misconception Origin: The idea of an age cutoff stems from past policies related to the older, less effective Zostavax vaccine.

  • High Effectiveness in Seniors: Shingrix is over 90% effective in adults aged 70 and older, providing robust protection that lasts for many years.

  • Reduces Severe Complications: Vaccination is particularly important for older adults as it significantly reduces the risk of painful complications like postherpetic neuralgia (PHN).

  • Superior to Old Vaccine: Shingrix offers far better and longer-lasting immunity than the discontinued Zostavax, making it the recommended choice even for those previously vaccinated.

In This Article

The Origins of a Misconception: A Tale of Two Vaccines

The idea that the shingles vaccine is unavailable after age 79 is a common point of confusion, but it is based on outdated information and policies. Historically, the older, live-attenuated vaccine known as Zostavax was in use. Because its effectiveness waned significantly with advanced age, some national immunization programs, particularly those rationing a limited supply, set an upper age limit. As research cited by Northern Ireland health authorities demonstrates, the vaccine's effectiveness was considered to diminish substantially in people aged 80 and over, leading to eligibility cutoffs. However, this is no longer the case with the current vaccine.

The Game-Changing Shingrix Vaccine

The modern recombinant shingles vaccine, Shingrix, represents a significant leap forward in protection. Approved in 2017, Shingrix replaced Zostavax and provides superior, longer-lasting immunity. It is for this reason that leading health organizations, including the CDC, emphasize that there is no maximum age for receiving Shingrix. Studies have shown that Shingrix remains highly effective in older adults, providing strong protection against shingles and its painful complication, postherpetic neuralgia (PHN). Experts encourage everyone aged 50 and over to get vaccinated, including those well past 80 years old.

Why Risk and Vaccination Both Increase with Age

Your risk of developing shingles and the severity of its symptoms increase with age. This is because your immune system naturally weakens over time, a process known as immunosenescence. This decline in immunity allows the varicella-zoster virus, which remains dormant in your nervous system since a childhood chickenpox infection, to reactivate. The older you get, the more vulnerable you are to this viral reactivation, making vaccination even more critical.

Key reasons shingles vaccination is important for older adults:

  • Higher Efficacy: Unlike its predecessor, Shingrix maintains a high level of effectiveness well into advanced age. For adults 70 and older, it is still over 90% effective at preventing shingles.
  • Reduced Complications: The risk of developing long-term nerve pain (PHN), which can last for months or years, increases with age. Shingrix has proven highly effective at preventing PHN in older adults, significantly improving quality of life.
  • Prevents Severe Disease: Older adults are more likely to experience severe shingles, which can lead to complications like vision loss, pneumonia, and in rare cases, brain inflammation. The vaccine significantly reduces the risk of such severe outcomes.

Comparison: Shingrix vs. Zostavax

Feature Shingrix (Current Vaccine) Zostavax (Discontinued Vaccine)
Vaccine Type Recombinant subunit vaccine (non-live) Live-attenuated vaccine
Effectiveness (Age 70+) ~91% effective against shingles ~41% effective against shingles
Protection Against PHN (Age 70+) ~89% effective ~65% effective
Doses Required Two doses One dose
Maximum Age Limit No maximum age Previously had an upper age cutoff (e.g., 79 in some programs)
Immunity Strong and long-lasting (over a decade) Wanes more quickly over time

Can Adults over 79 Still Get Vaccinated?

Yes. A conversation with your healthcare provider is the best way to determine eligibility, but for healthy adults, there is no upper age limit for receiving the Shingrix vaccine. This is a vital distinction from the era of Zostavax. The CDC and other health experts, like those at UCHealth, state that older individuals benefit greatly from the robust protection Shingrix offers. Even if you received Zostavax in the past, a discussion with your doctor about getting the superior Shingrix vaccine is recommended.

Frequently Asked Questions

  • Can you get shingles vaccine if you are 80? Yes, absolutely. There is no maximum age for receiving the Shingrix vaccine, and health officials recommend it for healthy adults age 50 and older. The vaccine remains highly effective even for those in their 80s and 90s.
  • What was the old shingles vaccine's age limit? The older Zostavax vaccine had a less durable effect in older adults. Due to waning effectiveness with increasing age, some national immunization programs set eligibility cutoffs around age 79 or 80 for the routine program.
  • Is Shingrix better for older adults than the old vaccine? Yes. Shingrix is significantly more effective and offers longer-lasting protection against shingles and its complications, including postherpetic neuralgia, for adults of all ages, including those 70 and older.
  • Why did I hear that the vaccine wasn't recommended after a certain age? The advice you heard was likely based on the older Zostavax vaccine or specific regional immunization program policies that are no longer current. The introduction of the far more effective Shingrix vaccine has made that advice obsolete.
  • Can an older adult who is immunocompromised get the shingles vaccine? Yes. Shingrix is a non-live vaccine, making it safe for many individuals with compromised immune systems. For immunocompromised adults age 19 and older, the CDC recommends vaccination, with some modifications to the dosing schedule. Always consult a healthcare provider to confirm eligibility.
  • How effective is Shingrix for adults over 70? Clinical trial data showed Shingrix was 91% effective in preventing shingles in adults 70 years and older. It was also 89% effective in preventing postherpetic neuralgia (PHN) in the same age group.
  • Does Medicare cover the shingles vaccine for seniors over 79? The specifics of insurance coverage depend on your plan, but Medicare Part D generally covers the shingles vaccine. Since there is no upper age limit for Shingrix recommendations, coverage is not restricted by age in the same way past policies were. It is best to check with your specific plan.

Conclusion: The Final Word on Age and Shingles Vaccination

The notion that there is an age limit for the shingles vaccine, specifically around 79, is a lingering misconception from a bygone era of vaccination. The advent of the superior Shingrix vaccine, which is non-live and highly effective well into advanced age, has eliminated any clinical rationale for an upper age cutoff. Health authorities universally recommend Shingrix for all healthy adults aged 50 and over, regardless of their age beyond that point. For those with compromised immune systems, eligibility starts even earlier, at age 19. It is crucial for older adults to be aware of the facts surrounding the modern shingles vaccine, as it offers a powerful defense against a painful and potentially debilitating disease.

For more information on the current shingles vaccine recommendations, consult the CDC Shingles Vaccination page.

Frequently Asked Questions

Yes, absolutely. There is no maximum age for receiving the Shingrix vaccine, and health officials recommend it for healthy adults age 50 and older. The vaccine remains highly effective even for those in their 80s and 90s.

The older Zostavax vaccine had a less durable effect in older adults. Due to waning effectiveness with increasing age, some national immunization programs set eligibility cutoffs around age 79 or 80 for the routine program.

Yes. Shingrix is significantly more effective and offers longer-lasting protection against shingles and its complications, including postherpetic neuralgia, for adults of all ages, including those 70 and older.

The advice you heard was likely based on the older Zostavax vaccine or specific regional immunization program policies that are no longer current. The introduction of the far more effective Shingrix vaccine has made that advice obsolete.

Yes. Shingrix is a non-live vaccine, making it safe for many individuals with compromised immune systems. For immunocompromised adults age 19 and older, the CDC recommends vaccination, with some modifications to the dosing schedule. Always consult a healthcare provider to confirm eligibility.

Clinical trial data showed Shingrix was 91% effective in preventing shingles in adults 70 years and older. It was also 89% effective in preventing postherpetic neuralgia (PHN) in the same age group.

The specifics of insurance coverage depend on your plan, but Medicare Part D generally covers the shingles vaccine. Since there is no upper age limit for Shingrix recommendations, coverage is not restricted by age in the same way past policies were. It is best to check with your specific plan.

References

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider regarding personal health decisions.